



16th ANNUAL MEETING NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS "PARTICIPATE AND EDUCATE"

**FRIDAY JANUARY 28, 6:00 PM - 9:00 PM RECEPTION
IN THE GLASS HOUSE
DIRTY HABIT RESTAURANT, HOTEL MONACO**

**SATURDAY, JANUARY 29
ALL SESSIONS ARE IN THE PARIS ROOM, HOTEL MONACO**

AGENDA

SESSION NAME	TIME	
Breakfast	8:00 – 8:45	
I. THE BASICS		
1. Introduction and Welcome	9:00-9:10	*Merel Nissenberg, Esq.
2. Prostate Cancer 101:	9:10-9:35	*Vincent Laudone, MD Memorial Sloan Kettering, New York
3. Prostate Cancer Genetics	9:35-10:00	*Atish Choudhury, MD Dana Farber (Harvard), Boston
4. Critical Aspects of Prostate Cancer Pathology	10:00-10:40	*Jonathan Epstein, MD Johns Hopkins, Baltimore
5. The ABC's of Androgen Deprivation Therapy and Anti-Androgens	10:40-11:10	*Mark Markowski, MD Johns Hopkins; *Michael Morris, MD Memorial Sloan Kettering
MORNING BREAK	11:10-11:15	
II. TREATMENT OF DISEASE BASED ON RISK ASSESSMENT		
6. Risk Assessment of Disease for Treatment Planning	11:15-11:45	*Vincent Laudone, MD Memorial Sloan Kettering
7. Basics of Prostate Cancer- Immuno-Oncology and Immuno-Therapeutics	11:45-12:15	*Saul Priceman, PhD City of Hope, Los Angeles, California and Immuno-oncologists in the Audience

LUNCH	12:15-1:00	Paris Room
8. Imaging Agents, The Role of PSMA Lutetium, Theranostics and Radioligand Therapy	1:05-1:30	*Michael Morris, MD Memorial Sloan Kettering
9. Low Risk Localized PCa: Genomic Tests, Focal Treatment and Active Surveillance	1:30-2:05	*Vincent Laudone, MD Memorial Sloan Kettering Daniel Song, MD Johns Hopkins
10. Multimodal Therapy for Intermediate and High Risk Disease	2:05-2:40	*Vincent Laudone, MD Memorial Sloan Kettering *Andrew Armstrong, MD, MSc Duke University
11. Imaging and Theranostics: Thera-P and VISION Trials	2:45-3:05	*Michael Morris, MD Memorial Sloan Kettering
III. A SYSTEMATIC APPROACH TO SYSTEMIC THERAPY		
12. Precision Medicine in Advanced Prostate Cancer; Chemotherapy Options	3:05-3:20	*Andrew Armstrong, MD, MSc Duke University
13. Untreated Metastatic Prostate Cancer	3:20-3:55	*Mark Markowski, MD Johns Hopkins
14. Non-Metastatic Castrate Resistant Prostate Cancer (nmCRPC)	3:20-3:55	*Atish Choudhury, MD Dana Farber (Harvard), Boston
AFTERNOON BREAK	3:55-4:10	
15. Biochemical/PSA Recurrence of Prostate Cancer	4:10-4:40	*Ashley Ross, MD, PhD Northwestern Memorial Hospital
16. Updates in Management of Men Newly-Diagnosed with Metastatic Prostate Cancer	4:40-5:00	*Andrew Armstrong, MD, MSc Duke University
17. Treatment of DNA Repair-Deficient Prostate Cancer	5:05-5:25	*Emmanuel Antonarakis, MD U of Minnesota

ADJOURN *****		
<u>Dinner starts at</u>	<u>6:30 P.M.</u>	<u>Paris Room, Hotel Monaco</u>

SUNDAY, JANUARY 30

AGENDA

SESSION NAME	TIME	
Breakfast Current Update on the CDMRP and DOD Research Funding	8:00-8:45	Mark Vieth, CRD Associates
IV. OPTIMIZING NASPCC: HOW CAN WE HELP STATES AND PATIENTS?		
18. State Coalitions Best Practices & Memorandum of Understanding	9:00-9:50	*Clarence Williamson, *Dwight Thomas, *David Sauls, *Fran Franklin, *Bruce Williams, *Chris Collier
19. PROSTATEPEDIA Magazine and DIGEST — Going Forward	9:50-10:00	*Jessica Myers-Schecter
20. “My Story”	10:05-10:20	*Brian McCloskey
21. Patient Navigators	10:20-10:35	*Cara Clements
22. PROMISE Registry	10:35-10:50	*Jenny Chiang
ELECTIONS for 2022 Officers and Board	10:50-11:10	Jan Marfyak, Secretary
BREAK	11:10-11:15	
V. FROM THE PATIENT’S PERSPECTIVE		
23. How to Approach Decision-Making: Medical and Patient Perspectives	11:15-11:45	*Michael Zaragoza, MD *Dave Hulbert, *Bruce Williams *Brian McCloskey
24. Report from the Chair of STEERING COMMITTEE	11:45-12:15	*Thomas Kirk, Chair and Advisory Committee Chairs
LUNCH	12:15-1:00	
25. What Lies Ahead for NASPCC? A New 5-Year STRATEGIC PLAN	1:00-2:15	*LaTanya Patton and Attendees’ Discussion
26. Wrap Up; Calendaring and Conclusions	2:15-3:00	*Merel Nissenberg
<hr/>		
ADJOURN	3:00 p.m.	